Heron Therapeutics, Inc. (HRTX)
NASDAQ: HRTX · Real-Time Price · USD
1.490
0.00 (0.00%)
At close: Jan 16, 2026, 4:00 PM EST
1.498
+0.008 (0.54%)
After-hours: Jan 16, 2026, 7:07 PM EST
Heron Therapeutics Market Cap
Heron Therapeutics has a market cap or net worth of $273.21 million as of January 16, 2026. Its market cap has increased by 17.41% in one year.
Market Cap
273.21M
Enterprise Value
358.17M
1-Year Change
17.41%
Ranking
Category
Stock Price
$1.49
Market Cap Chart
Since December 1, 1998, Heron Therapeutics's market cap has increased from $127.40M to $273.21M, an increase of 114.45%. That is a compound annual growth rate of 2.85%.
Market Cap History
| Date | Market Cap | % Change |
|---|---|---|
| Jan 16, 2026 | 273.20M | 14.60% |
| Dec 31, 2025 | 238.40M | 2.45% |
| Dec 31, 2024 | 232.70M | -8.78% |
| Dec 29, 2023 | 255.10M | -14.17% |
| Dec 30, 2022 | 297.20M | -68.07% |
| Dec 31, 2021 | 930.70M | -51.60% |
| Dec 31, 2020 | 1.92B | -9.13% |
| Dec 31, 2019 | 2.12B | 4.57% |
| Dec 31, 2018 | 2.02B | 105.15% |
| Dec 29, 2017 | 986.50M | 92.15% |
| Dec 30, 2016 | 513.40M | -46.54% |
| Dec 31, 2015 | 960.40M | 227.11% |
| Dec 31, 2014 | 293.60M | 110.32% |
| Dec 31, 2013 | 139.60M | -15.24% |
| Dec 31, 2012 | 164.70M | 258.04% |
| Dec 30, 2011 | 46.00M | 154.14% |
| Dec 31, 2010 | 18.10M | -63.51% |
| Dec 31, 2009 | 49.60M | 281.54% |
| Dec 31, 2008 | 13.00M | -73.25% |
| Dec 31, 2007 | 48.60M | 39.66% |
| Dec 29, 2006 | 34.80M | -10.08% |
| Dec 30, 2005 | 38.70M | -6.30% |
| Dec 31, 2004 | 41.30M | -18.22% |
| Dec 31, 2003 | 50.50M | 146.34% |
| Dec 31, 2002 | 20.50M | -63.91% |
View and export this data all the way back to 1998. Sign Up Today.
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| Eli Lilly and Company | 929.76B |
| Johnson & Johnson | 526.82B |
| AbbVie | 378.84B |
| UnitedHealth Group | 299.85B |
| AstraZeneca | 291.69B |
| Novartis AG | 276.38B |
| Merck & Co. | 270.12B |
| Novo Nordisk | 268.23B |